FDA Awards Orphan Drug Designation for Brain Cancer Drug Development by Rosalind Franklin University Helix 51 Company

NORTH CHICAGO, Ill., Oct. 23, 2024 /PRNewswire/ — U.P. Oncolytics, a company in Rosalind Franklin University’s Helix 51 biomedical incubator, has been awarded Orphan Drug designation by the FDA’s Office of Orphan Products Development for its oncolytic virus-based therapy to treat…